表紙
市場調查報告書

Biomedtracker /目標設備追蹤:2020年第3季預測

Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

出版商 Datamonitor Healthcare 商品編碼 955915
出版日期 內容資訊 英文 52 Pages
商品交期: 最快1-2個工作天內
價格
Biomedtracker /目標設備追蹤:2020年第3季預測 Biomedtracker / Meddevicetracker Q3 2020 Outlook Report
出版日期: 2020年07月01日內容資訊: 英文 52 Pages
簡介

本報告提供2020年的第3季預測的藥物,設備,診斷,催化劑的交易相關調查,各藥物的特定phase,藥物類別,根據疾病群組的phase/PDUFA審查的成功概率與整體核准取得可能性(LOA)等。

成為對象的適應症:

  • 痤瘡
  • 急性骨髓性白血病(AML)
  • Angelman症候群
  • 躁鬱症
  • 心臟瓣膜手術
  • COVID-19
  • 瀰漫性大型B細胞淋巴癌(DLBCL)-NHL
  • 移植物抗宿主病(GVHD)-治療
  • A型血友病
  • 高草酸尿症
  • 缺血性中風
  • 嚴重抑鬱症(MDD)
  • 套細胞淋巴瘤-NHL
  • 多發性骨髓瘤(MM)
  • 多發性硬化症(MS)
  • 骨髓增生異常症候群(MDS)
  • 骨關節炎和骨關節炎的疼痛
  • 其他的眼科症狀(眼科)
  • 腎臟疾病/腎功能衰竭
  • 類風濕性關節炎(RA)
  • 硬皮症
  • 發作障礙(癲癇)
  • 脊髓性肌萎縮症

目錄

  • 目錄
  • 概要
  • 關於作者
  • 免責聲明
  • 來自2020年第2季預測報告的結果
  • 藥品
  • 痤瘡:Winlevi/Breezula(SKIN)
  • 急性骨髓性白血病(AML):Oral Azacitidine(BMY)
  • Angelman症候群:OV101 (OVID)
  • 躁鬱症:Caplyta(ITCI)
  • COVID-19:Actemra(RHHBY)
  • COVID-19:Kevzara(SNY)
  • 瀰漫性大型B細胞淋巴癌(DLBCL):MOR208-NHL(MOR)
  • 移植物抗宿主病(GVHD):Ryoncil - 治療(MESO)
  • A型血友病:Roctavian (BMRN)
  • 高草酸尿症:Lumasiran (ALNY)
  • 大憂鬱症性障礙(MDD)的Nuplazid (ACAD)
  • 大憂鬱症性障礙(MDD)的Nuplazid (ACAD)
  • 套細胞淋巴瘤的KTE-X19-NHL(GILD)
  • 多發性骨髓瘤(MM)的Belantamab Mafodotin(GSK)
  • 多發性硬化症(MS)的Arzerra(自體免疫)(NVS)
  • 骨髓增生異常症候群(MDS)的ASTX727(大塚)等
目錄
Product Code: #BMT

Overview

In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa's drug development benchmarking product utilizing Biomedtracker's LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the drug catalysts highlighted in our Biomedtracker / Meddevicetracker Q2 2020 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through Q3 2020.

Indications Covered:

  • Acne
  • Acute Myelogenous Leukemia (AML)
  • Angelman Syndrome
  • Bipolar Disorder
  • Cardiac Valve Surgery

COVID-19

  • Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
  • Graft vs. Host Disease (GVHD) - Treatment
  • Hemophilia A
  • Hyperoxaluria
  • Ischemic Stroke
  • Major Depressive Disorder (MDD)
  • Mantle Cell Lymphoma - NHL
  • Multiple Myeloma (MM)
  • Multiple Sclerosis (MS)
  • Myelodysplastic Syndrome (MDS)
  • Osteoarthritis and Osteoarthritis Pain
  • Other Ophthalmological Indications (Ophthalmology)
  • Renal Disease / Renal Failure
  • Rheumatoid Arthritis (RA)
  • Scleroderma
  • Seizure Disorders (Epilepsy)
  • Spinal Muscular Atrophy

TABLE OF CONTENTS

  • Contents
  • Summary
  • About the Author
  • Disclaimer
  • Outcomes of Biomedtracker's Large Impact Drug Catalysts from the Q2 2020 Outlook Report
  • Drugs
  • Winlevi / Breezula for Acne (SKIN)
  • Oral Azacitidine for Acute Myelogenous Leukemia (AML) (BMY)
  • OV101 for Angelman Syndrome (OVID)
  • Caplyta for Bipolar Disorder (ITCI)
  • Actemra for COVID-19 (RHHBY)
  • Kevzara for COVID-19 (SNY)
  • MOR208 for Diffuse Large B-Cell Lymphoma (DLBCL) - NHL (MOR)
  • Ryoncil for Graft vs. Host Disease (GVHD) - Treatment (MESO)
  • Roctavian for Hemophilia A (BMRN)
  • Lumasiran for Hyperoxaluria (ALNY)
  • Nuplazid for Major Depressive Disorder (MDD) (ACAD)
  • Nuplazid for Major Depressive Disorder (MDD) (ACAD)
  • KTE-X19 for Mantle Cell Lymphoma - NHL (GILD)
  • Belantamab Mafodotin for Multiple Myeloma (MM) (GSK)
  • Arzerra (Autoimmune) for Multiple Sclerosis (MS) (NVS)
  • ASTX727 for Myelodysplastic Syndrome (MDS) (Otsuka)
  • CNTX-4975 for Osteoarthritis and Osteoarthritis Pain (CNTX)
  • RVL-1201 for Other Ophthalmological Indications (Ophthalmology) (OSMT)
  • Veverimer for Renal Disease / Renal Failure (TCDA)
  • Filgotinib for Rheumatoid Arthritis (RA) (GILD)
  • Lenabasum for Scleroderma (CRBP)
  • Ganaxolone for Seizure Disorders (Epilepsy) (MRNS)
  • Risdiplam for Spinal Muscular Atrophy (RHHBY)
  • Devices
  • Portico TAVI System for Cardiac Valve Surgery (ABT)
  • Ischemic Stroke System (ISS) for Ischemic Stroke (BrainsGate)
  • Deals
  • Alexion to Acquire Portola
  • Neurotrope and Metuchen to Merge
  • Tetraphase to be Acquired by La Jolla Pharmaceuticals
  • Q3 2020 Large Impact Catalysts